Wolfgang Miesbach: Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Predicting Breakthrough Bleeding in Emicizumab-Treated Acquired Haemophilia A. Excellent work presented at ASH2025 by Fabius Pelzer addressing one of the most pressing challenges in acquired haemophilia A:
Despite emicizumab’s remarkable efficacy in preventing bleeds, up to 30% of patients still experience breakthrough bleeding—and we currently lack reliable predictive tools to identify who’s at risk.

This changes today.
Using FXIa-triggered thrombin generation (FXIa-TGA) as a surrogate biomarker, Pelzer and colleagues developed an innovative nomogram to assess individual bleeding risk based on:
- Peak thrombin generation potential
- Emicizumab levels
- Residual Factor VIII activity
Main findings:
- FXIa-TGA peak thrombin is more sensitive than conventional TGA to low factor levels and emicizumab concentrations
- Both emicizumab and residual Factor VIII significantly influence peak thrombin generation in the multivariable model
- Higher peak thrombin values correlated with lower bleeding rates (IRR 0.40 [0.17-0.84])
This is precision haemostasis and enables patient-specific risk stratification in real time. Moving beyond one-size-fits-all dosing to truly personalized management of AHA.

Having a functional biomarker that predicts individual risk opens pathways for:
- Optimized prophylactic dosing strategies
- Early detection of patients requiring intervention
- Better understanding of emicizumab mechanism in real-world AHA
Congratulations to Fabius, Andreas Tiede and the entire GTH study team on this rigorous work that has now been published in Haematologica Journal.”
Read more posts from Wolfgang Miesbach on Hemostasis Today.
-
Nov 11, 2026, 13:46Danny Gaskin: Recognising Iron Deficiency Before Anaemia
-
Nov 11, 2026, 13:46James P. Crowley: Newborn Vitamin K Refusal a 347% Surge in Life-Threatening Bleeding
-
Nov 11, 2026, 13:42Manideepa Maji: IV Iron Safety in Heart Failure
-
Nov 11, 2026, 13:36Wilson Andrés Vásconez Samaniego: NGS-Based Genomic Profiling Before Gene Therapy for Hemoglobinopathies
-
Nov 11, 2026, 13:34Mathieu Jackson: WFH Opens Registration for 2027 Comprehensive Care Summit
-
Nov 11, 2026, 13:29Maia Meier: Recognising Bleeding Disorders Through the 7-2-1 Rule
-
Nov 11, 2026, 13:17Kiran Rajeev T: Elsevier Releases New Practical Handbook on Transfusion Medicine
-
Nov 11, 2026, 13:01Reza Shojaei: FDA Approval Marks Milestone for Factor XIa-Targeted Therapy
-
Nov 11, 2026, 11:35Paulus Kirchhof: Oral Anticoagulation in Atrial Fibrillation After Intracranial Hemorrhage